COMP <GO>
KNSA vs ALKS // EV/EBITDA & P/E VALUATION
Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) VS. Alkermes plc (NASDAQ) • 15-METRIC TALLY: KNSA 5
— ALKS 8
▲ EV/EBITDA & P/E VALUATION LEADER: ALKS
LAST: $90.80 (-1.56%) • MKT CAP: $7.25B
valuation
95.0x
LAST: $44.89 (-0.99%) • MKT CAP: $7.61B
valuation
25.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. ALKS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | ALKS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 86.70% | +1.80 | KNSA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 14.00% | -4.10 | ALKS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 25.1x | +69.90 | ALKS | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | 6.31% | -4.53 | ALKS | /fcf-yield <GO> |
| Operating Margin | 11.40% | 17.20% | -5.80 | ALKS | /operating-margins <GO> |
| Net Profit Margin | 8.70% | 16.40% | -7.70 | ALKS | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | -5.20% | +65.30 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.45 | 8.03 | +16.42 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.2 | 61.0 | -1.80 | ALKS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.05 | +0.06 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 109.1x | 29.3x | +79.80 | ALKS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.25B | $7.61B | -$358.9M | ALKS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | ALKS REV | KNSA GROSS % | ALKS GROSS % | KNSA FCF | ALKS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | $1.48B | 88.5% | 86.7% | $136.4M | $480.3M |
| FY 2024 | $423.2M | $1.56B | 85.6% | 84.2% | $25.4M | $405.6M |
| FY 2023 | $270.3M | $1.66B | — | — | $1.1M | $326.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
ALKS // BETA 1.05